VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Preventing progression of smoldering myeloma to multiple myeloma with anti-myeloma therapies

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on preventing the progression of smoldering myeloma to multiple myeloma, discussing therapeutic strategies that are currently being evaluated in this setting, including triplet and quadruplet therapies as well as bispecific antibodies and CAR-T therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter